Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.

Cancer Immunology, Immunotherapy : CII
Yu YaoLiangfu Zhou

Abstract

Dendritic cell (DC)-based vaccination is a promising approach for active-specific immunotherapy, but is currently of limited efficacy. The safety and effectiveness of a DC vaccine (DCV) loaded with glioblastoma stem cell-like (GSC) antigens was assessed in glioblastoma multiforme (GBM) patients. In this double-blind, placebo-controlled phase II clinical trial, 43 GBM patients were randomized after surgery at a 1:1 ratio to receive either DCV (n = 22) or normal saline placebo (n = 21). Overall survival (OS) and progression-free survival (PFS) were analysed. Participants were stratified into different molecular subgroups based on the mutation (MT) status of isocitrate dehydrogenase (IDH1/2) and telomerase reverse transcriptase (TERT). Plasma cytokine levels, tumor-infiltrating lymphocyte numbers and immune co-inhibitory molecules PD-L1 and B7-H4 were also assessed. Multivariate Cox regression analysis revealed that DCV treatment significantly prolonged OS (p = 0.02) after adjusting for IDH1 and TERT promoter MT and B7-H4 expression, primary vs recurrent GBM. Among IDH1wild type (WT) TERTMT patients, DCV treatment significantly prolonged OS (p < 0.01) and PFS (p = 0.03) and increased plasma levels of cytokines CCL22 and IFN-γ comp...Continue Reading

Associated Clinical Trials

References

Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jan 30, 2007·Laboratory Investigation; a Journal of Technical Methods and Pathology·Milena CankovicRichard J Zarbo
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonDarell D Bigner
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert M PrinsLinda M Liau
Jan 18, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Anna M DahlinRichard Palmqvist
Mar 23, 2012·Nature Reviews. Cancer·Karolina Palucka, Jacques Banchereau
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jun 25, 2013·Cancer Treatment Reviews·Amade BregyRicardo J Komotar
Jan 11, 2014·Cancer Immunology Research·Tiffany DoucetteAmy B Heimberger
Aug 2, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Aden Ka-Yin ChanHo-Keung Ng
Dec 2, 2014·Cell Reports·Hyungjun JeonXingxing Zang
Jun 11, 2015·The New England Journal of Medicine·Jeanette E Eckel-PassowRobert B Jenkins
Sep 2, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon
Mar 24, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu YaoLiangfu Zhou
Nov 22, 2016·The Lancet Oncology·Vicki Brower

❮ Previous
Next ❯

Citations

Aug 14, 2019·Current Opinion in Oncology·Valérie DutoitPierre-Yves Dietrich
Oct 3, 2019·Cancers·Theodoulakis ChristofiApostolos Zaravinos
Nov 14, 2019·Current Topics in Medicinal Chemistry·Vadim V TarasovGjumrakch Aliev
Oct 28, 2019·Oncoimmunology·Jenny SprootenAbhishek D Garg
May 28, 2020·Journal for Immunotherapy of Cancer·Di ChenLiangfu Zhou
Nov 21, 2020·Immunology and Cell Biology·Laverne D RobilliardE Scott Graham
Dec 31, 2020·Cancers·Stefaan W Van GoolWilfried Stuecker
Feb 16, 2021·Frontiers in Immunology·Xi ZhangHongyan Guo
Nov 13, 2020·Frontiers in Immunology·Joshua R D PearsonStephanie E B McArdle
Mar 6, 2021·Nanomedicine : Nanotechnology, Biology, and Medicine·Hendrik Setia BudiFarhad Jadidi-Niaragh
Mar 27, 2021·Expert Review of Vaccines·Xiaoling XuYun Fan
Apr 4, 2021·Cancers·Nathalie OlympiosMaxime Fontanilles
Aug 11, 2021·Pharmaceutics·Jasmine L King, Soumya Rahima Benhabbour
Aug 24, 2021·Frontiers in Immunology·Aida KarachiMaryam Rahman
Jan 26, 2022·Expert Review of Vaccines·Parisa ShamshiripourMahzad Akbarpour
Feb 3, 2022·Current Neurology and Neuroscience Reports·Michael ZhangMichael Lim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.